Trastuzumab-DM4
Trastuzumab-DM4 is an antibody-drug conjugate (ADC) formed by conjugating Trastuzumab (HY-P9907) with DM4 (sulfo-SPDB-DM4) (HY-101141) via a cleavable linker. DM4 is a tubulin inhibitor that suppresses cell division. Trastuzumab-DM4 significantly inhibits tumor growth in Trastuzumab-resistant HER2 xenograft tumor models. Trastuzumab-DM4 can be used for the research of HER2-positive breast cancer.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:nu/nu (female)[1]
-
Dosage:10 mg/kg
-
Administration:i.v.; single injection
-
Result:Significantly inhibited tumor growth.
Chemical Information
-
SMILES
[Trastuzumab-DM4]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Trastuzumab-DM4 Related Classifications
HY-185718 Related Classifications
Powered by Bioz
- Trastuzumab-DM4
- Antibody-Drug Conjugates (ADCs)
- Microtubule/Tubulin
- trastuzumab-resistant HER2-overexpressing breast cancer mouse model
- HER2-overexpressing tumor cells
- her2-positive breast cancer
- BT-474 breast carcinoma cells
- MCF7 breast carcinoma cells
- beige nude mice
- SK-BR-3 breast carcinoma cells
- Inhibitor
- inhibitor
- inhibit